公司資料
bioAffinity Technologies, Inc. 股價、新聞與催化劑
- 股票代碼:
- BIAF
- 交易所:
- NASDAQ
- 產業:
- MedTech
- 所在地:
- United States
股票表現
0.39 USD (-2.51%)
收盤價
最後更新: 2026年8月17日
7.62M USD
市值
股價為何變動
The latest monitored company update is “bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung.” The corresponding closing-price reaction is not yet available.
公司概覽
Noninvasive Lung Diagnostics
bioAffinity Technologies develops noninvasive tests for the early detection and characterization of lung disease. Its approach uses flow-cytometry and artificial-intelligence analysis of cells collected from sputum samples.
CyPath Lung
CyPath Lung is a laboratory-developed test intended to help assess patients at elevated risk of lung cancer, including those with indeterminate imaging findings. It is positioned between imaging surveillance and invasive diagnostic procedures. The company is also exploring applications of its cellular-analysis platform in asthma and chronic obstructive pulmonary disease, including potential companion-diagnostic uses.
未來催化劑
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。